Rafael Amado
2019 - Allogene Therapeutics
In 2019, Rafael Amado earned a total compensation of $7.5M as Chief Medical Officer and Executive Vice President of Research and Development at Allogene Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $71,726 |
|---|---|
| Option Awards | $2,759,623 |
| Salary | $145,833 |
| Stock Awards | $4,249,976 |
| Other | $225,000 |
| Total | $7,452,158 |
Amado received $4.2M in stock awards, accounting for 57% of the total pay in 2019.
Amado also received $71.7K in non-equity incentive plan, $2.8M in option awards, $145.8K in salary and $225K in other compensation.
Rankings
In 2019, Rafael Amado's compensation ranked 1,242nd out of 13,971 executives tracked by ExecPay. In other words, Amado earned more than 91.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,242 out of 13,971 | 91st |
Division Manufacturing | 433 out of 5,695 | 92nd |
Major group Chemicals And Allied Products | 133 out of 2,194 | 94th |
Industry group Drugs | 106 out of 1,880 | 94th |
Industry Biological Products, Except Diagnostic Substances | 24 out of 389 | 94th |
Source: SEC filing on April 23, 2020.
Amado's colleagues
We found three more compensation records of executives who worked with Rafael Amado at Allogene Therapeutics in 2019.
News
Allogene Therapeutics CEO David Chang's 2021 pay jumps 30% to $10M
April 26, 2022
Allogene Therapeutics CEO David Chang's 2020 pay falls 30% to $7.8M
April 22, 2021
Allogene Therapeutics CEO David Chang's 2019 pay slips 13% to $11M
April 23, 2020
Adaptimmune Therapeutics CEO James Noble's 2018 pay jumps 58% to $2.6M
March 15, 2019